AC Immune And Takeda Sign Exclusive Option and License Agreement For Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease, AC Immune To Receive Upfront Payment Of $100M And Is Eligible ~$2.1B In Milestone
AC Immune And Takeda Sign Exclusive Option and License Agreement For Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease, AC Immune To Receive Upfront Payment Of $100M And Is Eligible ~$2.1B In Milestone
AC Immune和武田簽署針對阿爾茨海默氏病β澱粉樣蛋白的活性免疫療法的獨家期權和許可協議，AC Immune將獲得1億美元的預付款，並且有資格獲得約21億美元的里程碑
AC Immune And Takeda Sign Exclusive Option and License Agreement For Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease, AC Immune To Receive Upfront Payment Of $100M And Is Eligible ~$2.1B In Milestone
AC Immune和武田簽署針對阿爾茨海默氏病β澱粉樣蛋白的活性免疫療法的獨家期權和許可協議，AC Immune將獲得1億美元的預付款，並且有資格獲得約21億美元的里程碑
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。